Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards
10:00am, Tuesday, 03'rd Feb 2026
Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp
Natera Submits Signatera™ CDx PMA to FDA
06:00am, Monday, 02'nd Feb 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food an
Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of “Moderate Buy” from Analysts
02:00am, Monday, 02'nd Feb 2026
Natera, Inc. (NASDAQ: NTRA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat reports. One rese
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
01:22pm, Thursday, 29'th Jan 2026
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
08:00am, Wednesday, 28'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-con
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care
06:00am, Monday, 26'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new prospective clinical trial in Transplanta
Alger Small Cap Growth Fund Q4 2025 Portfolio Update
03:54am, Monday, 26'th Jan 2026
Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were
GDS Wealth Management Has $11.61 Million Holdings in Natera, Inc. $NTRA
05:24am, Sunday, 25'th Jan 2026
GDS Wealth Management lifted its holdings in shares of Natera, Inc. (NASDAQ: NTRA) by 11.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exc
Steven Leonard Chapman Sells 1,590 Shares of Natera (NASDAQ:NTRA) Stock
05:22am, Saturday, 24'th Jan 2026
Natera, Inc. (NASDAQ: NTRA - Get Free Report) CEO Steven Leonard Chapman sold 1,590 shares of the company's stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an
Alger Mid Cap Focus Fund Q4 2025 Portfolio Update
05:15am, Thursday, 22'nd Jan 2026
Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Roblox Corp., Robinhood Markets, Inc., and Nebius Group were among the top detractor
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
06:00am, Wednesday, 21'st Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study
Alger Capital Appreciation Fund Q4 2025 Portfolio Update
12:58pm, Tuesday, 20'th Jan 2026
Class A shares of the Alger Capital Appreciation Fund underperformed the Russell 1000 Growth Index during the fourth quarter of 2025. Alphabet Inc., Western Digital Corporation, and Natera, Inc. were
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary
Campbell & CO Investment Adviser LLC Acquires Shares of 5,145 Natera, Inc. $NTRA
04:31am, Tuesday, 20'th Jan 2026
Campbell and CO Investment Adviser LLC bought a new stake in Natera, Inc. (NASDAQ: NTRA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchan
Alger Spectra Fund Q4 2025 Portfolio Update
10:20am, Monday, 19'th Jan 2026
Class A shares of the Alger Spectra Fund underperformed the Russell 3000 Growth Index during the fourth quarter of 2025. Alphabet Inc., Natera, Inc., and Cidara Therapeutics, Inc. were among the top c
